BioSapien has just announced the completion of its extended pre-Series A funding round with a total amount of $7 million. Golden Gate Ventures, led the investment through its dedicated MENA Fund in this investment. The infused capital will further speed up the clinical trials and development of the flagship product of BioSapien, MediChip™, an innovative platform for localized cancer therapy.

About BioSapien

Founded in 2018 by CEO Khatija Ali, BioSapien is a pioneering healthtech company headquartered in the United Arab Emirates. The company is focused on developing innovative solutions in the field of oncology, aimed at improving patient outcomes through advanced technology. BioSapien’s mission is to make localized cancer treatment the global standard, thereby reducing the systemic side effects commonly associated with traditional therapies.

Read also: Leyden Labs a Dutch biotech has raised $70M in funding

The MediChip™ Platform

At the heart of BioSapien’s innovation is MediChip™, a 3D-printed, slow-release drug delivery platform designed to attach directly to tissues. This technology enables the localized delivery of chemotherapy agents, targeting tumors more effectively while minimizing systemic exposure. 

The result is a reduction in the adverse side effects typically associated with conventional chemotherapy treatments. MediChip™ represents a significant advancement in personalized cancer therapy, offering a more targeted and patient-friendly approach to treatment.

The extended pre-Series A funding round, which now stands at $7 million, attracted new strategic investors in the form of Golden Gate Ventures. This funding is the first deployment by the dedicated MENA Fund of Golden Gate Ventures into BioSapien, with a strong vote of confidence that the innovative approach of BioSapien to cancer treatment may have a greater impact. The fund will be helpful in advancing clinical trials and scaling up manufacturing capacity. 

Read also: Retro Biosciences Aims to Extend Human Lifespan with $1 Billion Funding Initiative

Strategic Importance of the UAE

The United Arab Emirates has been at the forefront of adopting forward-thinking healthcare initiatives, making it an ideal environment for BioSapien’s expansion. The country’s commitment to leveraging advanced technology to enhance quality of life aligns seamlessly with BioSapien’s mission. 

The upcoming clinical trials in Abu Dhabi not only represent a significant milestone for the company but also underscore the UAE’s growing prominence as a global hub for health innovation

Ongoing/Upcoming Clinical Trials

The new funding is expected to see BioSapien speed up clinical trials of MediChip™ in the UAE, with enrollment of patients slated to start in Abu Dhabi during the second quarter of 2025. The clinical trials will seek to confirm the safety and efficacy of the MediChip™ platform in providing targeted cancer treatment. A successful clinical trial may pave the way for more widespread application of the technology, which can potentially change the standard of care in oncology.

Investor Views

Michael Lints, Partner at Golden Gate Ventures MENA, comments, “BioSapien is an excellent fit for our investment thesis-to support transformative technologies that address pressing global challenges.

 This is not merely an investment in a disruptive technology but a bet on a future where the gulf region becomes the leader in healthcare innovation.” This also resonates with the growing acknowledgment that the MENA region has much potential to contribute towards global progress in medical technology.

Read also: Leyden Labs a Dutch biotech has raised $70M in funding

Future Prospect

BioSapien is now well on its way to revolutionizing cancer treatment after raising additional funding in its round. The company intends to use the new capital to accelerate clinical trials, scale manufacturing capabilities, and attract top-tier talent to its team. 

Looking ahead, BioSapien will impact over one million patients by 2035, starting with colorectal cancer and expanding to other cancer types and various medical indications. The company’s innovative approach holds the promise of making localized cancer treatment a global standard, significantly improving patient outcomes worldwide.